NovaGo Therapeutics AG, a clinical-stage biotechnology company developing anti-Nogo-A biologics for diseases of the central nervous system, has successfully closed its Series B financing round of USD 30 million – an important step to advance its lead program into a proof-of-concept study in patients with acute spinal cord injury. The financing round was co-led by Pureos Bioventures and Neurimmune AG with participation from existing and new investors.

VISCHER advised Pureos Bioventures on all Swiss legal issues related to the financing. The VISCHER team comprised Matthias Staehelin (partner, Corporate/M&A), Tobias F. Rohner (partner, Tax) and Natacha Tang (associate, Corporate/M&A).

Read the press release here: https://www.novagotherapeutics.com/2026/09/02/series-b-financing-of-usd-30m-completed-in-august-2026/